Novartis and Par Exforge price-fixing $30M class action settlement

Updates:

• Readers reported this settlement paying out up to $8,201.99 as of Dec. 8, 2023.
• Congratulations to everyone who filed a claim and got paid!

• The court granted this settlement final approval on Oct. 11, 2023.

• Let Top Class Actions know when you receive a check in the comments section below or on our Settlements & Payouts Facebook group.

Novartis has agreed to a $30 million antitrust class action settlement to end claims it engaged in a price-fixing scheme with company Par for the blood pressure medication commonly known as Exforge.

The settlement benefits anyone who purchased or paid for brand and generic Exforge from Sept. 21, 2012, through June 30, 2018, in the District of Columbia, Arizona, California, Florida, Hawaii, Iowa, Maine, Michigan, Minnesota, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, South Dakota, Utah, Vermont, West Virginia or Wisconsin.

The lawsuit alleged Novartis, the manufacturer of Exforge, and Par, a generic pharmaceutical company, entered into an agreement where Novartis agreed not to sell an authorized generic version of Exforge until six months after Par began selling its generic version of Exforge. 

In exchange, Par agreed to delay the launch of its generic Exforge product for approximately two years. The lawsuit alleges the companies violated certain state antitrust, consumer protection, and unjust enrichment laws, harming competition and causing people to overpay for brand and generic Exforge. 

Novartis is a Swiss multinational pharmaceutical corporation based in Switzerland. It is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022. Par has declared bankruptcy and is not contributing to the settlement fund. 

To be eligible to receive a payment if the Exforge antitrust settlement is approved, class members must complete and submit a valid claim form with evidence from their pharmacy or doctor to request their pro rata share of the net settlement fund. 

Class members will not be responsible for calculating the amount they are entitled to receive.

Class members who wish to exclude themselves from or object to the Exforge antitrust class action settlement must do so no later than Aug. 18, 2023.

The court has scheduled a fairness hearing for Oct. 3, 2023.

The deadline to submit a claim form is Aug. 18, 2023.

Who’s Eligible

The settlement benefits anyone who purchased or paid for brand and generic Exforge from Sept. 21, 2012, through June 30, 2018, in the District of Columbia, Arizona, California, Florida, Hawaii, Iowa, Maine, Michigan, Minnesota, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, South Dakota, Utah, Vermont, West Virginia or Wisconsin.

Potential Award

TBD

Proof of Purchase

Records from your pharmacy or a note from your doctor demonstrating that you bought Exforge or its generic. 

Claim Form

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

08/18/2023

Case Name

In re: Novartis and Par Antitrust Litigation, Case No. 1:18-cv-04361, in the U.S. District Court for the Southern District of New York

Final Hearing

10/03/2023

Settlement Website

ExforgeAntitrustSettlement.com

Claims Administrator

Novartis and Par Antitrust Litigation
c/o Claims and Notice Administrator
1650 Arch Street, Suite 2210
Philadelphia, PA 19103
info@exforgeantitrustsettlement.com
833-741-2334

Class Counsel

Robin A van der Meulen
DICELLO LEVITT LLP

Defense Counsel

Rachel Skaistis 
CRAVATH SWAINE & MOORE LLP